0.19
+0.0123(+6.84%)
Currency In USD
| Previous Close | 0.18 |
| Open | 0.18 |
| Day High | 0.24 |
| Day Low | 0.18 |
| 52-Week High | 33.66 |
| 52-Week Low | 0.16 |
| Volume | 99.5M |
| Average Volume | 9.22M |
| Market Cap | 5.29M |
| PE | -0.46 |
| EPS | -0.43 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 2.01 |
| Change | 0.02 |
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
GlobeNewswire Inc.
Feb 17, 2026 1:44 PM GMT
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
GlobeNewswire Inc.
Oct 30, 2025 2:04 PM GMT
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Underst
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
GlobeNewswire Inc.
Jul 28, 2025 11:30 AM GMT
Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold Up to $500 Million for Long-Term Strategic ValueLA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus